The Board has recommended Dividend of Rs. 0.90 per share subject to approval of Shareholders at ensuing Annual General Meeting
MARKSANS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 14.7 pts more than Nifty Microcap 250 and 15.3 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Marksans Pharma's Board has recommended a final dividend of Rs. 0.90 per share (90% of face value of Re. 1) for FY 2025-26, subject to shareholder approval at the AGM. The company reported strong full-year results with consolidated revenue of Rs. 29,509 million (up 12.5% YoY) and consolidated PAT of Rs. 4,201 million (up 9.8% YoY). Standalone PAT grew 61% to Rs. 3,006 million. The dividend amounts to approximately Rs. 40.8 crore based on 453.16 million outstanding shares. The payout ratio is modest at around 9.7% of consolidated PAT, indicating healthy retained earnings for growth investments. The dividend will be paid within 30 days of the AGM date.
The dividend signals confidence in the company's financial health and cash generation ability. The modest payout ratio suggests room for future dividend increases while funding expansion. Positive for income-seeking investors but limited impact on stock price.